Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+status: Updated results from the phase 3 IKEMA study.

被引：0
|
作者：
Facon, Thierry
Moreau, Philippe
Spicka, Ivan
Suzuki, Kenshi
Yong, Kwee
Mikhael, Joseph
Fukao, Taro
Bisht, Kamlesh
Armstrong, Nicole
Mace, Sandrine
Risse, Marie-Laure
Martin, Thomas G.
机构：
[1] Lille Univ Hosp, Dept Hematol, Lille, France
[2] Univ Hosp Nantes, Dept Hematol, Nantes, France
[3] Charles Univ Prague, Gen Fac Hosp, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[5] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan
[6] Univ Coll Hosp, Dept Haematol, London, England
[7] City Hope Canc Ctr, Translat Genom Res Inst, Appl Canc Res & Drug Discovery, Phoenix, AZ USA
[8] Sanofi, Global Oncol, Cambridge, MA USA
[9] Sanofi, Global Med Affairs, Cambridge, MA USA
[10] Sanofi, Res & Dev, Chilly Mazarin, France
[11] Sanofi, Res & Dev, Vitry Sur Seine, France
[12] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8029
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) In Relapsed Multiple Myeloma Patients With 1q21+Status: Updated Results From The Phase 3 IKEMA Study
    Thierry, Facon
    Philippe, Moreau
    Ivan, Spicka
    Kenshi, Suzuki
    Kwee, Yong
    Joseph, Mikhael
    Taro, Fukao
    Kamlesh, Bisht
    Nicole, Armstrong
    Sandrine, Mace
    Marie-Laure, Risse
    Thomas, Martin
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S26 - S26
  • [2] Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study
    Facon, Thierry
    Moreau, Philippe
    Spicka, Ivan
    Suzuki, Kenshi
    Yong, Kwee
    Mikhael, Joseph
    Fukao, Taro
    Bisht, Kamlesh
    Armstrong, Nicole
    Mace, Sandrine
    Risse, Marie-Laure
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S484 - S485
  • [3] Isatuximab in combination with carfilzomib and dexamethasone in 1q21+patients with relapsed/refractory multiple myeloma: Long-term outcomes in the Phase 3 IKEMA study
    Facon, Thierry
    Moreau, Philippe
    Spicka, Ivan
    Suzuki, Kenshi
    Yong, Kwee
    Mikhael, Joseph
    Fukao, Taro
    Bisht, Kamlesh
    Armstrong, Nicole M.
    Mace, Sandrine
    Risse, Marie-Laure
    Martin, Thomas
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
  • [4] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
    Thomas Martin
    Meletios-Athanasios Dimopoulos
    Joseph Mikhael
    Kwee Yong
    Marcelo Capra
    Thierry Facon
    Roman Hajek
    Ivan Špička
    Ross Baker
    Kihyun Kim
    Gracia Martinez
    Chang-Ki Min
    Ludek Pour
    Xavier Leleu
    Albert Oriol
    Youngil Koh
    Kenshi Suzuki
    France Casca
    Sandrine Macé
    Marie-Laure Risse
    Philippe Moreau
    Blood Cancer Journal, 13
  • [5] Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma
    Martin, Thomas
    Dimopoulos, Meletios-Athanasios
    Mikhael, Joseph
    Yong, Kwee
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S403 - S404
  • [6] Updated Progression-free Survival (PFS) and Depth of Response in IKEMA, A Randomized Phase 3 Trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma (MM)
    Mikhael, Joseph
    Moreau, Philippe
    Dimopoulos, Meletios-Athanasios
    Yong, Kwee
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Martin, Thomas
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S37 - S38
  • [7] Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
    Yong, Kwee
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Mikhael, Joseph
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S194 - S195
  • [8] Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study (vol 13, 152, 2023)
    Martin, Thomas
    Dimopoulos, Meletios-Athanasios
    Mikhael, Joseph
    Yong, Kwee
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Baker, Ross
    Kim, Kihyun
    Martinez, Gracia
    Min, Chang-Ki
    Pour, Ludek
    Leleu, Xavier
    Oriol, Albert
    Koh, Youngil
    Suzuki, Kenshi
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [9] Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
    Martin, Thomas G.
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Moreau, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
    Moreau, P.
    Dimopoulos, M. A. C.
    Mikhael, J.
    Yong, K.
    Capra, M.
    Facon, T.
    Hajek, R.
    Spicka, I.
    Casca, F.
    Mace, S.
    Singh, E.
    Risse, M-L.
    Martin, T.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 664 - 665
12345